Q1 2025 Earnings Call Transcript May 13, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Lexicon Pharmaceuticals' Q1 2025 highlights include a transformative Novo Nordisk partnership, Phase 3 plans for pilavapadin in DPNP, and refocused ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 11.08%, which has investors questioning if this is right time ...

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.20 per share a year ago. These ...

On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 7 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

Along with the proliferation of AI companies has come a proliferation of AI company logos. The fascinating thing, highlighted by several publications, is that many of these logos look near-identical.

NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 ...

NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 ...

Jazz Pharmaceuticals (JAZZ) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the conditional marketing ...

As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum ...